La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Hepion Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Hepion Pharmaceuticals..

Hepion Pharmaceuticals (NASDAQ:HEPA) Azioni, Catena delle Opzioni

Hepion Pharmaceuticals

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals Inc

Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) affirms FY2025 Adj EPS guidance from $0.90-$1.30 to $0.90-$1.30 vs $0.99 analyst estimate. Affirms FY2025 sales outlook from $1.48 billion-$1.62 billion to $1.48 billion-$1.62 billion vs $1.48 billion estimate.

News

Guidance

Nu Skin Enterprises Affirms FY2025 Adj EPS Guidance of $0.90-$1.30 vs $0.99 Est; Affirms FY2025 Sales Guidance of $1.48B-$1.62B vs $1.48B Est

Earnings

Earnings Misses

PTMN

Portman Ridge Finance Q1 NII $0.47 Misses $0.63 Estimate, Total Inv Income $12.12M Miss $14.87M Estimate

Strattec Security (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRT#NASDAQ">STRT</a>) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $0.95 by 38.95 percent. This is a 256.76 percent increase over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $144.08 million which beat the analyst consensus estimate of $140.84 million by 2.30 percent. This is a 2.35 percent increase over sales of $140.77 million the same period last year.

Earnings Beats

STRT

Strattec Security Q3 EPS $1.32 Beats $0.95 Estimate, Sales $144.08M Beat $140.84M Estimate

Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(0.91) by 1.1 percent. This is a 13.92 percent decrease over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $1.57 million which missed the analyst consensus estimate of $1.90 million by 17.21 percent. This is a 55.60 percent decrease over sales of $3.54 million the same period last year.

Avidity Biosciences Q1 EPS $(0.90) Beats $(0.91) Estimate, Sales $1.57M Miss $1.90M Estimate

Options include AWS and Microsoft with artificial intelligence and data options
As cloud use cases continue to expand, Alaska Communications is teaming up with industry leader Slalom to provide advanced cloud offerings for Alaska enterprises and government organizations.
From enabling more efficient and sustainable exploration in the oil and gas industry to opening a world of real-time collaboration and learning opportunities in public education, managed cloud helps unlock innovation for Alaska.
Alaska Communications and Slalom offer services through Amazon Web Services (AWS) and Microsoft platforms, which include:
<ul>
<li>Planning and Migration - Evaluate cloud readiness. Plan and execute the move to the cloud.</li>
<li>Automation and Innovation - Build a digital operating model in the cloud, automate operations and compliance.</li>
<li>Optimization and Modernization - Tune cloud footprint for efficiency, cost and value.</li>
</ul>
This partnership also leverages Slalom's leadingartificial intelligence AI and data capabilities as added service offerings to help Alaska companies power their operations and gain a competitive advantage.
"Alaska's tough hiring market makes it challenging to find IT professionals with the specialized skills needed to operate cloud environments at peak efficiency," said Dale Knipp, senior vice president, business, Alaska Communications. "Alaska Communications is the gateway of modern technology for our clients in Alaska, and we're excited to help our clients maximize the benefits of cloud services, AI and data in the most cost-effective manner possible."
"To compete today, every business needs cloud technology," said Jayson Stangel, Managing Director, Slalom. "With Alaska Communications' deep knowledge of Alaska and its advanced fiber network combined with our expertise in cloud, AI and data consulting, customers can expect a tailored mix of services to support their unique needs and business goals."
"With a solid cloud foundation in place, the future is bright for Alaska enterprises and the services they provide to residents," said Knipp.

Contracts

ATNI

Alaska Communications And Slalom Enters Partnership To Deliver Managed Cloud Solutions For Alaska Enterprises

Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.48) by 14.58 percent. This is a 7.89 percent decrease over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $3.67 million which missed the analyst consensus estimate of $4.38 million by 16.05 percent. This is a 76.88 percent decrease over sales of $15.89 million the same period last year.

ALEC

Alector Q1 EPS $(0.41) Beats $(0.48) Estimate, Sales $3.67M Miss $4.38M Estimate

WIIM

HUBS

HubSpot shares are trading lower after the company reported Q1 financial results. The company issued Q2 adjusted EPS guidance below estimates.

Rumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.10) by 90 percent. This is a 95.24 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $23.71 million which beat the analyst consensus estimate of $23.07 million by 2.75 percent. This is a 33.69 percent increase over sales of $17.73 million the same period last year.

Rumble Q1 EPS $(0.01) Beats $(0.10) Estimate, Sales $23.71M Beat $23.07M Estimate

WOLF

Wolfspeed shares are trading lower. The company reported mixed Q3 financial results

Sana Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.23) by 13.04 percent. This is a 37.5 percent increase over losses of $(0.32) per share from the same period last year.

SANA

Sana Biotechnology Q1 Adj. EPS $(0.20) Beats $(0.23) Estimate

MNTK

Montauk Renewables shares are trading lower. The company reported Q1 financial results.

INOD

Innodata Inc shares are trading lower. The company reported Q1 financial results

Innospec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOSP#NASDAQ">IOSP</a>) reported quarterly earnings of $1.42 per share which met the analyst consensus estimate. This is a 18.86 percent decrease over earnings of $1.75 per share from the same period last year. The company reported quarterly sales of $440.80 million which missed the analyst consensus estimate of $462.03 million by 4.60 percent. This is a 11.88 percent decrease over sales of $500.20 million the same period last year.

IOSP

Innospec Q1 Adj. EPS $1.42, Inline, Sales $440.80M Miss $462.03M Estimate

Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) raises Q4 sales outlook from $810.00 million-$840.00 million to $815.00 million-$845.00 million vs $841.42 million estimate.

AFRM

Affirm Holdings Raises Q4 Sales Guidance from $810.00M-$840.00M to $815.00M-$845.00M vs $841.42M Est

Tyra Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.48) by 2.08 percent. This is a 34.29 percent decrease over losses of $(0.35) per share from the same period last year.

TYRA

Tyra Biosciences Q1 EPS $(0.47) Beats $(0.48) Estimate

FY 2025 We continue to expect fiscal year 2025 net revenue in the range of $295 million to $310 million with an Adjusted EBITDA margin in the mid-single digit percentage range, excluding non-routine items.

Eventbrite Affirms FY2025 Sales Guidance of $295.00M-$310.00M vs $301.19M Est

Cryptocurrency company Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) reported first-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Thursday.</a>
Here are the highlights.
What Happened: Coinbase reported first-quarter total revenue of $2.03 billion. It missed a Street consensus estimate of $2.12 billion, according to data from Benzinga Pro.
Total revenue was up from $1.64 billion in last year's first quarter and down 10% from $2.27 billion in the fourth quarter.
Transaction revenue was $1.26 billion in the first quarter, up from $1.08 billion in last year's first quarter and down 19% quarter-over-quarter.
Subscription and services revenue was $698.1 million, which was in the company's previous guidance range of $685 million to $765 million. This revenue segment was up 9% quarter-over-quarter.
Adjusted earnings per share of $1.94 missed a Street consensus estimate of $2.11 for the quarter.
"This quarter, we made meaningful progress against our 2025 priorities of driving revenue, driving utility, and building the foundations to power the next decade of growth," the company said.
Coinbase said it gained market share in global spot and derivatives in the quarter.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) made up 27% of trading volume and 26% of transaction revenue, nearly identical to 27% for both metrics in the fourth quarter. Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) was 11% of trading volume and 10% of transaction volume, compared to 10% for both in the fourth quarter.
Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) represented 10% of transaction revenue in the first quarter and was less than 10% in the prior month.
XRP Token (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) represented 11% of trading volume and 18% of transaction revenue. In the fourth quarter, the crypto was 14% of transaction revenue and under 10% of trading volume.
Read Also: <a href="https://www.benzinga.com/25/05/45265214/coinbase-q1-earnings-preview-trump-inauguration-bitcoin-surge-and-more-items-to-watch">Coinbase Q1 Earnings Preview: Trump Inauguration, Bitcoin Surge And More Items To Watch</a>
What's Next: Coinbase highlighted sector progress, citing President Donald Trump&#8216;s executive order to establish a Strategic Bitcoin Reserve.
The company also said the dismissal of the SEC lawsuit against Coinbase was a "major judicial win."
"With growing regulatory clarity, we're accelerating our vision towards economic freedom," the company said.
Coinbase also highlighted its previous announced acquisition of Sentilia B.V (Deribit), a leading crypto options exchange. The acquisition is expected to close by the end of the year.
Guidance from Coinbase calls for second-quarter subscription and services revenue in a range of $600 million to $680 million.
April transaction revenue for the company was $240 million.
COIN Price Action: Coinbase stock is down 2.4% to $201.51 in after-hours trading Thursday. Its 52-week trading range is $142.58 to $349.75.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43713994/coinbase-q4-earnings-highlights-revenue-beat-consumer-trading-volume-940-billion-company-welcomes-dawn-of-a-new-era-for-crypto">Coinbase Acquires Deribit In $2.9B Deal To Expand Crypto Derivatives Business</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

Trading Ideas

$BTC

$ETH

$SOL

$XRP

COIN

Coinbase Slips On Q1 Miss, Highlights SEC 'Win' And Deribit Deal

BLND

Blend Labs shares are trading higher. The company reported Q1 financial results.

Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.13 by 76.92 percent. This is a 155.56 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $364.49 million which beat the analyst consensus estimate of $352.06 million by 3.53 percent. This is a 12.66 percent decrease over sales of $417.31 million the same period last year.

Nu Skin Enterprises Q1 Adj. EPS $0.23 Beats $0.13 Estimate, Sales $364.49M Beat $352.06M Estimate

INVESTOR PRESENTATION Q2 2025 Based on current information, we anticipate net revenue for the second quarter of 2025 to be within the range of $70 to $73 million and Adjusted EBITDA margin in the 3% to 4% range, excluding non-routine items. The quarterly sequential trends in net revenue and Adjusted EBITDA margin are driven largely by the timing of Easter, delays of some large events into the second half of the year, and typical quarter-to-quarter mix-shift in average ticket prices.

Eventbrite Sees Q2 Sales $70.000M-$73.000M vs $74.92M Est

Press Releases

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B

Health Care

General

Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

Hepion Pharmaceuticals Announces $9.0 Million Public Offering

Hepion Pharmaceuticals Announces Reverse Stock Split

Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

Comments

Hepion Pharmaceuticals

Hepion Pharmaceuticals (HEPA) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO